{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.","groups":[{"description":"Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"5-FU, Cisplatin, Radiation and Iressa"}],"paramType":"NUMBER","populationDescription":"5 early deaths were not evaluable","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants With No Distant Metastatic Disease at 1 Year","type":"PRIMARY","unitOfMeasure":"participants"}